Company Overview

Sarepta Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on the discovery, development, and commercialization of precision genetic medicines for rare neuromuscular diseases. The company primarily operates in the biotechnology and rare disease therapeutics industries, with a concentrated emphasis on Duchenne muscular dystrophy (DMD) and other genetically defined disorders. Sarepta’s core capabilities center on RNA-targeted therapies and gene therapy, leveraging proprietary platforms to address the underlying genetic causes of disease rather than symptoms alone.

The company’s primary revenue drivers are its FDA-approved DMD therapies, including Exondys 51, Vyondys 53, and Amondys 45, which are exon-skipping antisense oligonucleotide treatments, as well as Elevidys, a gene therapy approved for certain DMD patients. Sarepta serves a specialized patient population within the rare disease community, primarily pediatric and young adult patients, and is uniquely positioned as a market leader in DMD due to its early-mover advantage, deep clinical expertise, and vertically integrated development and manufacturing capabilities. Founded in 1980 as AVI BioPharma, the company rebranded as Sarepta Therapeutics in 2012 to reflect its strategic shift toward rare genetic diseases and precision medicine.

Business Operations

Sarepta operates through a single integrated business model focused on research and development, manufacturing, and commercialization of genetic medicines. Its operations are organized around two principal therapeutic platforms: RNA-targeted antisense oligonucleotide therapies and AAV-based gene therapies, both of which support its DMD and broader neuromuscular disease pipeline. Revenue is generated primarily from product sales in the United States, supplemented by collaboration revenue and milestone payments from strategic partners.

The company maintains in-house manufacturing capabilities for clinical and commercial supply, including control over key technologies related to RNA chemistry and viral vector production. Sarepta conducts international operations primarily through partnerships rather than direct commercial infrastructure. A significant collaboration includes its global partnership with Roche, which holds ex-U.S. commercialization rights for Elevidys, while Sarepta retains U.S. rights and certain manufacturing responsibilities. The company also operates multiple wholly owned subsidiaries that support research, development, and manufacturing functions.

Strategic Position & Investments

Sarepta’s strategic direction is centered on expanding its leadership in DMD while broadening its genetic medicine pipeline into additional neuromuscular and rare genetic diseases, including limb-girdle muscular dystrophies (LGMDs). Key growth initiatives include lifecycle expansion of Elevidys, continued development of next-generation RNA therapies, and investment in scalable manufacturing technologies to support future gene therapy launches. The company has made sustained capital investments in internal manufacturing infrastructure to reduce reliance on third parties and improve supply reliability.

Notable strategic investments include long-term collaboration agreements, most prominently with Roche, which included upfront payments, equity investment, and downstream milestones tied to Elevidys. Sarepta also continues to invest heavily in emerging technologies such as novel capsids, gene expression optimization, and precision delivery systems to enhance efficacy and safety across its pipeline. These initiatives are intended to support both near-term commercial growth and long-term platform sustainability.

Geographic Footprint

Sarepta Therapeutics is headquartered in Cambridge, Massachusetts, and its primary commercial activities are concentrated in the United States, which represents the vast majority of its current revenue base. The company also maintains research, manufacturing, and operational facilities in other parts of the U.S. to support development and production activities.

Internationally, Sarepta’s presence is largely driven through strategic partnerships rather than direct sales operations. Through its collaboration with Roche, the company has indirect market exposure across Europe, Asia-Pacific, and other global regions where Roche is responsible for regulatory filings, commercialization, and distribution. This partnership-based model allows Sarepta to exert global influence while maintaining a focused operational footprint.

Leadership & Governance

Sarepta was not founded by its current leadership team, but its modern strategic vision has been shaped by executives with deep experience in biotechnology, rare diseases, and regulatory engagement. The leadership philosophy emphasizes scientific rigor, patient-focused development, and disciplined capital allocation, with a stated commitment to addressing diseases with high unmet medical need through innovative genetic approaches.

Key members of Sarepta’s executive leadership include:

• Douglas S. Ingram – President and Chief Executive Officer
• Ian T. Estepan – Executive Vice President and Chief Financial Officer
• Louise Rodino-Klapac, Ph.D. – Executive Vice President and Chief Scientific Officer
• Diane J. Berry – Senior Vice President and Chief Legal Officer
• Todd L. Manning – Executive Vice President, Global Manufacturing and Supply

The company is governed by a board of directors with experience spanning biotechnology, pharmaceuticals, finance, and corporate governance, and operates under standard U.S. public company governance practices as reflected in its SEC filings, including annual and quarterly reports.